HYFT MindWalk Holdings Corp.
USHealthcareAs of 2026-07-10 16:00
Why HYFT matters now
MindWalk Holdings Corp. (HYFT) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.43 with -2.05% on the session and $66.8M in market capitalization; recent performance reads 1-month +21.43% and YTD -15.93%.
The latest financial table shown here is Q3 2026, with revenue of $4.1M, net income of $-3.9M, and EPS of $-0.08. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -11.8%.
The latest indexable market news headline is "MindWalk Holdings Corp. (NASDAQ: HYFT) Added to the Russell 3000E Index, Expanding Institutional Investment Opportunity" from GuruFocus.
Additional event context on this page matters because analyst consensus is Buy with a median target of $5.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
6.73
P/S
5.51
EV/EBITDA
-8.32
DCF Value
$-5.35
FCF Yield
-11.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
60.3%
Operating Margin
-65.3%
Net Margin
-66.4%
ROE
-63.2%
ROA
-52.6%
ROIC
-63.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $4.1M | $-3.9M | $-0.08 |
| Q2 2026 | $4.1M | $-3.2M | $-0.07 |
| Q1 2026 | $3.2M | $-3.0M | $-0.07 |
| Q4 2025 | $7.0M | $-2.2M | $-0.06 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$5.00
Target (Median)
$5.00
Target Range
$5.00 - $5.00
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
CA
Exchange
—
Beta
0.82
MindWalk Holdings Corp. functions as an innovative bio-native artificial intelligence firm. Its core mission involves leveraging the synergy of AI, comprehensive multi-omics data, and sophisticated laboratory investigations to accelerate the identification and advancement of biological therapeutics. Utilizing its proprietary LensAI platform and HYFT technology, the company forges partnerships with pharmaceutical and biotechnology enterprises. These collaborations are designed to diminish the inherent risks associated with drug development and to unlock new possibilities for treatments. Founded in 1983, the company adopted its current name, MindWalk Holdings Corp., in September 2025, having previously been known as ImmunoPrecise Antibodies Ltd. Its corporate headquarters are located in Austin, Texas.